Annual General Meeting of Curatis Holding AG approved all proposals of the
Board of Directors

Curatis Holding AG / Key word(s): AGMEGM
Annual General Meeting of Curatis Holding AG approved all proposals of the
Board of Directors

21.06.2024 / 17:13 CET/CEST

---------------------------------------------------------------------------

MEDIA RELEASE

Liestal, Switzerland, 21 June 2024: Curatis Holding AG (CURN.SW), a SIX
Swiss Exchange listed specialty pharmaceutical and therapeutic drug
development company focused on orphan and ultra-orphan indications today
held its Annual General Meeting.

The shareholders of Curatis Holding AG voted in favour of all proposals of
the Board of Directors and have approved all resolutions relating to the
annual report and the financial year 2023 of the company, the change of
auditor to Forvis Mazars, the board and management compensation as well as
selected adjustments to the articles of associations with large majorities.

The shareholders present (85.43% percent of voting rights) also re-elected -
for a further term of 1 year - all members of the board, consisting of
Marian Borovsky (Chairman, independent), Günter Graubach, Roland Rutschmann
and Silvio Inderbitzin (independent). As members of the compensation
committee, Marian Borovsky, Roland Rutschmann and Günter Graubach were
re-elected for a term of 1 year.

About the Curatis Group
Curatis Holding AG is a publicly listed specialty pharmaceutical company
with a distribution and drug development business. The focus of the Curatis
Group's business activities is on high unmet medical need orphan and
ultra-orphan indications, pursued via its wholly owned operating subsidiary
Curatis AG. The Curatis Group was formed by the business combination of
Kinarus Therapeutics Holding AG and Curatis AG in April 2024.

Investors Relations contact:
YUMA Capital
Thomas Bieri
Managing Partner
Tel: +41 44 575 20 01
thomas.bieri@yuma-capital.com

Disclaimer
This document contains certain forward-looking statements. Other written
materials, as well as other written and oral statements made to the public,
may also contain forward-looking statements. Forward-looking statements can
be identified by words such as "potential," "expected," "will," "planned,"
"pipeline," "outlook," "may," "could," "would," "anticipate," "seek," or
similar terms, or by express or implied discussions regarding potential new
products, potential new indications for existing products, or regarding
potential future revenues from any such products; or regarding the potential
outcome, or financial or other impact on Curatis Holding AG, of any of the
transactions carried out; or regarding potential future sales or earnings of
the group or any of its divisions or potential shareholder returns; or by
discussions of strategy, plans, expectations or intentions. Such
forward-looking statements are based on the current beliefs and expectations
of management regarding future events, and are subject to significant known
and unknown risks and uncertainties. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the
forward-looking statements. You should not place undue reliance on these
statements.


---------------------------------------------------------------------------

End of Media Release

---------------------------------------------------------------------------

   Language:       English
   Company:        Curatis Holding AG
                   Weierweg 7
                   4410 Liestal
                   Switzerland
   ISIN:           CH1330780979
   Listed:         SIX Swiss Exchange
   EQS News ID:    1930923

End of News EQS News Service
---------------------------------------------------------------------------

1930923 21.06.2024 CET/CEST